AXIOS January 4, 2024
The Food and Drug Administration is examining reports of suicidal thoughts and other possible side effects linked to a class of blockbuster obesity drugs and whether it needs to take regulatory action.
Driving the news: An update to the agency’s adverse event reporting system cited the risk of suicidal ideation; alopecia, or hair loss; and inhalation of stomach contents is connected to drugs treating diabetes and weight loss that include Wegovy, Ozempic, Mounjaro and Zepbound.
- While the FDA cautioned there’s no certainty that a suspected drug is responsible for side effects reported to the agency, past investigations have led to new warnings on drug labels, more safety studies and other precautions.
- Eli Lilly, the maker of Mounjaro and Zepbound,...
Today's Sponsors
Today's Sponsor